Tunlametinib (HL-085) Plus Vemurafenib in Patients with Advanced BRAF V600-mutant Solid Tumors: an Open-Label, Single-Arm, Multicenter, Phase I Study
EXPERIMENTAL HEMATOLOGY & ONCOLOGY（2024）
关键词
Tunlametinib,MEK inhibitor,Vemurafenib,BRAF,Non-small cell lung cancer,Colorectal cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要